BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naclerio GA, Abutaleb NS, Li D, Seleem MN, Sintim HO. Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo. J Med Chem 2020;63:11934-44. [PMID: 32960605 DOI: 10.1021/acs.jmedchem.0c01198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Tortajada-Girbés M, Rivas A, Hernández M, González A, Ferrús MA, Pina-Pérez MC. Alimentary and Pharmaceutical Approach to Natural Antimicrobials against Clostridioides difficile Gastrointestinal Infection. Foods 2021;10:1124. [PMID: 34069413 DOI: 10.3390/foods10051124] [Reference Citation Analysis]
2 Suigo L, Chojnacki M, Zanotto C, Sebastián-Pérez V, Morghen CG, Casiraghi A, Dunman PM, Valoti E, Straniero V. Staphylococcus aureus RnpA Inhibitors: Computational-Guided Design, Synthesis and Initial Biological Evaluation. Antibiotics (Basel) 2021;10:438. [PMID: 33920000 DOI: 10.3390/antibiotics10040438] [Reference Citation Analysis]
3 Naclerio GA, Onyedibe KI, Karanja CW, Aryal UK, Sintim HO. Comparative Studies to Uncover Mechanisms of Action of N-(1,3,4-Oxadiazol-2-yl)benzamide Containing Antibacterial Agents. ACS Infect Dis 2022. [PMID: 35297603 DOI: 10.1021/acsinfecdis.1c00613] [Reference Citation Analysis]
4 Onyedibe KI, Dayal N, Sintim HO. SF5- and SCF3-substituted tetrahydroquinoline compounds as potent bactericidal agents against multidrug-resistant persister Gram-positive bacteria. RSC Med Chem 2021;12:1879-93. [PMID: 34825185 DOI: 10.1039/d1md00211b] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Naclerio GA, Abutaleb NS, Alhashimi M, Seleem MN, Sintim HO. N-(1,3,4-Oxadiazol-2-yl)Benzamides as Antibacterial Agents against Neisseria gonorrhoeae. Int J Mol Sci 2021;22:2427. [PMID: 33671065 DOI: 10.3390/ijms22052427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
7 Naclerio GA, Abutaleb NS, Onyedibe KI, Karanja C, Eldesouky HE, Liang HW, Dieterly A, Aryal UK, Lyle T, Seleem MN, Sintim HO. Mechanistic Studies and In Vivo Efficacy of an Oxadiazole-Containing Antibiotic. J Med Chem 2022;65:6612-30. [PMID: 35482444 DOI: 10.1021/acs.jmedchem.1c02034] [Reference Citation Analysis]
8 Glomb T, Świątek P. Antimicrobial Activity of 1,3,4-Oxadiazole Derivatives. Int J Mol Sci 2021;22:6979. [PMID: 34209520 DOI: 10.3390/ijms22136979] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chang M, Mahasenan KV, Hermoso JA, Mobashery S. Unconventional Antibacterials and Adjuvants. Acc Chem Res 2021;54:917-29. [PMID: 33512995 DOI: 10.1021/acs.accounts.0c00776] [Reference Citation Analysis]
10 Abutaleb NS, Elhassanny AEM, Nocentini A, Hewitt CS, Elkashif A, Cooper BR, Supuran CT, Seleem MN, Flaherty DP. Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae. J Enzyme Inhib Med Chem 2022;37:51-61. [PMID: 34894972 DOI: 10.1080/14756366.2021.1991336] [Reference Citation Analysis]